Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into Arrowhead’s RNA interference (RNAi) pipeline, capital structure, collaborations, and material events affecting ARWR stock.
Arrowhead’s filings include Form 8-K current reports describing key developments such as approvals for REDEMPLO (plozasiran) in familial chylomicronemia syndrome, Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia, interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7, and the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies including Alzheimer’s disease. Other 8-Ks outline collaboration agreements, such as the exclusive license with Novartis for ARO-SNCA, and agreements involving Visirna Therapeutics and Sanofi in Greater China.
Filings also cover Arrowhead’s capital markets transactions, including underwriting agreements for public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032. These documents describe offering terms, use of proceeds for research and development, clinical trials, commercialization activities, and related capped call transactions intended to manage potential dilution upon note conversion.
On Stock Titan, Arrowhead’s SEC filings are updated in near real time from EDGAR. Users can review annual and quarterly reports when available, as well as current reports and exhibits that detail licensing deals, clinical milestones, and regulatory actions. AI-powered summaries help explain complex sections of 10-Ks, 10-Qs, and 8-Ks in plain language, and specialized views make it easier to track insider-related disclosures and other material information relevant to ARWR investors.
Form 144 notice: The filer proposes to sell 20,000 shares of common stock through Merrill Lynch on 10/01/2025 with an aggregate market value of $700,014.67. The issuer has 138,257,550 shares outstanding. The securities to be sold were acquired as compensation in multiple grants between 01/04/2022 and 01/04/2025 totaling 63,232 shares granted across six dated entries. In the past three months the reporting person sold 40,000 shares on four dates (08/13/2025, 08/15/2025, 09/02/2025, 09/12/2025) generating aggregate gross proceeds of $1,024,880.20. The filer attests they have no undisclosed material adverse information and includes the standard Rule 144 representations.
James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported a sale of 15,000 shares of common stock on 09/12/2025 at $30 per share under a pre-established 10b5-1 trading plan. After the transaction he beneficially owns 232,122 shares, which includes previously reported shares underlying restricted stock units, some of which remain subject to vesting.
The Form 4 discloses the transaction and the reporting person’s relationship to the issuer (Officer and Director). The filing clarifies the sale was pursuant to the trading plan and that a portion of the reported holdings represents unvested restricted stock units.
Arrowhead Research Corporation (ARWR) filed an 8-K reporting a material event that primarily contains forward-looking statement disclosures and a brief litigation update. The company states it intends to vigorously pursue its claims in an ongoing lawsuit and refers to planned commercialization efforts for its investigational drug plozasiran. The filing cites uncertainties tied to the Ionis letter, the validity and enforceability of the '333 Patent, the company’s broader patent portfolio, and the outcome of the lawsuit. It emphasizes that forward-looking statements are based on current expectations and that actual results may differ materially due to risks described in prior SEC filings.
Insider sale under 10b5-1 plan: James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported a sale of 15,000 shares of common stock executed pursuant to a Rule 10b5-1 trading plan at a price of $25 per share, reducing his reported beneficial ownership to 247,122 shares. The filing notes that the remaining reported shares include previously disclosed restricted stock units, some of which remain subject to vesting conditions. No options, warrants, or other derivative transactions are reported.
Arrowhead Research (ARWR) Form 144 notice: An individual identified as James Hamilton plans to sell 15,000 common shares through Merrill Lynch on 09/02/2025 with an aggregate market value of $374,970.05. The filing shows 138,257,550 shares outstanding for the issuer and names NASDAQ as the exchange.
The filing discloses the acquisition history for the shares being sold: multiple compensation grants between 01/04/2022 and 01/04/2025 totaling the reported units, and prior sales in August 2025 of 611 and 9,389 shares generating gross proceeds of $12,190.05 and $187,750.05, respectively. The filer affirms no undisclosed material adverse information.
Arrowhead Research entered an exclusive licensing agreement with Novartis for ARO-SNCA, a preclinical RNAi therapeutic targeting Parkinson's disease and other synucleinopathies. Arrowhead will complete preclinical work while Novartis is responsible for clinical development, manufacturing, and commercialization. Arrowhead will receive a $200 million upfront payment, potential up to $2 billion in development, regulatory, and sales milestones, and is eligible for tiered royalties up to the low double digits on net product sales. The transactions are subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period. The full agreement text will be filed as an exhibit to Arrowhead's annual report for the year ending September 30, 2025.
James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported two open-market sales of common stock executed under a Rule 10b5-1 trading plan. On 08/13/2025 he sold 611 shares at $20 per share and on 08/15/2025 he sold 9,389 shares at $20 per share, for total reported disposals of 10,000 shares at $20 each. After these transactions he beneficially owned 262,122 shares, down from 271,511 shares prior to the sales. The filing notes that the post-transaction total includes previously reported shares underlying restricted stock units, some of which remain subject to vesting conditions.
Amendment No. 1 to Schedule 13D updates prior disclosure that Sarepta Therapeutics, Inc. and its affiliate Sarepta Therapeutics Investments, Inc. no longer hold any shares of Arrowhead Pharmaceuticals, Inc. The amendment states that on August 13, 2025 Sarepta Investments sold 9,265,312 shares in a privately negotiated block trade at $18.79 per share and, concurrently, Sarepta Investments sold an additional 2,660,989 shares back to Arrowhead in a redemption under a Letter Agreement to satisfy a $49,999,983.31 milestone payment obligation. After these transactions the reporting persons beneficially own 0 shares (0.0% of the class) and ceased to be beneficial owners of more than 5% of Arrowhead's common stock.
This Form 144 notice states that 9,389 shares of common stock are proposed for sale through Merrill Lynch on 08/15/2025, with an aggregate market value of $187,750.05. The filing lists the number of shares outstanding as 138,257,550 and names the exchange as NASDAQ.
The securities were acquired as compensation from James Hamilton on multiple dates between 01/04/2022 and 01/04/2025, with specified lot sizes included. The filer also reported a recent sale of 611 shares on 08/13/2025 for gross proceeds of $12,190.05. The form includes the standard attestation that the person signing does not possess undisclosed material adverse information.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 11,517,441 shares of Arrowhead Pharmaceuticals common stock, representing 8.3% of the outstanding class. The reported position includes 917,441 shares issuable upon exercise of warrants and the percentage is calculated on an aggregate of 138,100,435 shares outstanding as disclosed in the company's quarterly report.
The filing states Avoro holds sole voting and sole dispositive power over these shares and that the holdings are held for investment purposes on behalf of Avoro Life Sciences Fund LLC. The filing notes the report should not be construed as an admission of beneficial ownership for Section 13 purposes.